← Back to Search

Monoclonal Antibodies

Dupilumab for Eczema

Phase 4
Recruiting
Led By Jeffrey Cheng, MD, PhD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18 years of age or older
Diagnosis of atopic dermatitis with a EASI (Eczema Area and Severity Index) score of 7 or higher
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 8-12 weeks
Awards & highlights

Study Summary

This trial looks at how blocking a particular protein affects skin inflammation in those with eczema.

Who is the study for?
This trial is for adults over 18 with moderate to severe eczema, as shown by an EASI score of 7 or more. It's not open to those who are pregnant, have a known parasitic infection, or suffer from immunodeficiencies.Check my eligibility
What is being tested?
The study is testing Dupilumab's effects on immune cells in skin lesions caused by atopic dermatitis (eczema) by blocking a specific part of the immune response thought to be involved in this condition.See study design
What are the potential side effects?
Dupilumab may cause side effects such as injection site reactions, eye and eyelid inflammation, cold sores in your mouth or on your lips, and rarely more serious allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
My eczema is severe, with a score of 7 or more.
Select...
My eczema is severe, with a score of 7 or higher.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 8-12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 8-12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Eczema Area and Severity Index (EASI) score from baseline to 8-12 weeks

Side effects data

From 2021 Phase 4 trial • 188 Patients • NCT04033367
12%
Accidental Overdose
2%
Conjunctivitis
2%
Nasopharyngitis
2%
Headache
2%
Dermatitis Atopic
1%
Fall
1%
Multiple Fractures
100%
80%
60%
40%
20%
0%
Study treatment Arm
DB Period: Placebo
OLE Period: Dupilumab/Dupilumab
DB Period: Dupilumab
OLE Period: Placebo/Dupilumab

Trial Design

1Treatment groups
Experimental Treatment
Group I: dupilumab treatmentExperimental Treatment1 Intervention
Treatment with IL4RA inhibitor
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dupilumab
2017
Completed Phase 4
~12230

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,507 Previous Clinical Trials
15,238,560 Total Patients Enrolled
Jeffrey Cheng, MD, PhDPrincipal InvestigatorUniversity of California, San Francisco
Raymond Cho, MD, PhDPrincipal InvestigatorUniversity of California, San Francisco
4 Previous Clinical Trials
85 Total Patients Enrolled

Media Library

Dupilumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05858619 — Phase 4
Atopic Dermatitis Research Study Groups: dupilumab treatment
Atopic Dermatitis Clinical Trial 2023: Dupilumab Highlights & Side Effects. Trial Name: NCT05858619 — Phase 4
Dupilumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05858619 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still vacancies for those eager to participate in this research?

"According to clinicaltrials.gov, this experiment has been open for recruitment since February 1st 2023 and was last revised on May 4th 2023. It is presently seeking patients."

Answered by AI

Are there any attendant risks associated with dupilumab therapy?

"The safety of dupilumab as a treatment option has been validated by Phase 4 clinical trials, and our team at Power gave it the highest rating on their 1 to 3 scale."

Answered by AI

What is the cap on enrollment for this clinical trial?

"Yes, according to clinicaltrials.gov, this research trial is still in search of eligible subjects. The study was initially posted on February 1st 2023 and has since been updated as recently as May 4th 2023. At present, the team needs 15 participants from a single site."

Answered by AI

Who else is applying?

What state do they live in?
California
What site did they apply to?
University of California, San Francisco
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

What questions have other patients asked about this trial?

How long do screenings take?
PatientReceived 2+ prior treatments
Recent research and studies
clinicaltrials.govStudy
Molecular Signatures of Cutaneous Dupilumab Response
2023. "Molecular Signatures of Cutaneous Dupilumab Response". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05858619.
All > Eczema
~9 spots leftby Feb 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top